STAT reports that an expert has warned obesity drugs based on GLP-1 may become the next major dispute over access to medicines in lower-income countries. The source points to concerns about how these new treatments will be distributed and priced outside wealthier markets.
This issue matters for pharma and healthcare leaders, as drug access and pricing are under increasing scrutiny from policymakers and the public. Companies may need to consider how their global strategies affect both reputation and regulatory risk.